Highlights

  • ALS Limited reported record FY26 Revenue of $3.32 billion, reflecting 10.7% growth, driven predominantly by a buoyant Commodities division where Minerals organic revenue surged 20.2% as the exploration cycle continued its upward momentum.
  • Underlying NPAT grew 25.8% to $381.2 million, supported by an expanding EBIT Margin of 18.0% — up 129 basis points — with Minerals margins achieving a fifth consecutive year above 30%, reaching 33.0% in FY26.
  • The company declared a final Dividend of 23.1 cents per share (30% partially franked), bringing the full-year dividend to 42.5 cents per share, representing a 10.1% increase on FY25 and a 57% Payout Ratio of underlying NPAT.

 

ALS Limited (ASX:ALQ), the Brisbane-headquartered global testing, inspection, and certification group, has delivered a landmark set of financial results for the fiscal year ended 31 March 2026. Revenue of $3.32 billion — a 10.7% increase on the prior corresponding period — reflects the company's ability to capture the benefits of a broad-based commodities exploration upswing while continuing to grow its Life Sciences operations, despite pockets of operational challenge in that division. Underlying NPAT of $381.2 million, up 25.8%, marks a new high watermark for the group.

From the perspective of share market performance, ALS has delivered handsomely for investors over the past year, with the stock gaining 27.56% in the twelve months to 18 May 2026, outperforming broader market indices and reflecting the market's recognition of the company's operational Leverage to the mineral exploration cycle. At AUD 22.59 on 18 May 2026, the stock added a further 1.76% intraday, indicating continued positive sentiment following the results announcement.

Commodities Division: Capturing the Exploration Upcycle

The Commodities division — comprising Minerals, Industrial Materials, and Coal — was the primary engine of ALS's FY26 outperformance. Revenue from Commodities grew 18.8% versus the prior corresponding period, driven by organic growth of 18.1%. Minerals, which forms the core of this division, benefitted from robust sample volumes as exploration activity accelerated across multiple geographies.

The global Mining sector entered FY26 with supportive Commodity price conditions, an accelerating energy transition driving Demand for critical minerals, and strong Capital raising activity among junior and mid-tier explorers. ALS's Minerals operation — the global Market Leader in geochemistry testing — was exceptionally well-positioned to capture this Volume growth. Geochemistry organic revenue grew 22.7%, with North America showing the strongest H2 improvement. Organic revenue across the Minerals division as a whole grew 20.2%, and the EBIT margin expanded 222 basis points to 33.0%, marking the fifth consecutive year that the division has exceeded the 30% threshold.

Industrial Materials also contributed positively, delivering strong organic revenue growth of 10.5%, with particular strength in Assay and Inspection. All Business units within this sub-segment generated meaningful organic growth, reflecting ALS's diverse exposure to the broader resources Supply chain beyond pure exploration.

Life Sciences: A Mixed Picture with Underlying Resilience

ALS's Life Sciences division — encompassing Environmental, Food, and Pharmaceutical testing — presented a more nuanced picture in FY26. Overall Life Sciences revenue increased 6.0%, with organic growth of 2.8%, scope growth of 0.7%, and a favourable currency tailwind of 2.6%. The underlying EBIT margin improved 55 basis points, with the reported margin expanding to 14.6%.

Food was the standout performer within Life Sciences, delivering organic revenue growth of 7.2%, supported by a compelling customer proposition in key European markets across both volume and pricing dimensions. Environmental, however, experienced softer trading conditions, particularly in the Americas, where the company encountered a combination of internal quality and cost challenges — now under remediation — and market-specific headwinds including project deferrals linked to the US Government Shutdown that impacted the third quarter. APAC and EMEA performed meaningfully better, both delivering mid-single-digit revenue growth.

In Pharmaceuticals, Nuvisan's two-year transformation program was completed in FY26, with an exit run rate of approximately €25 million in cost reductions achieved. Nuvisan's revenue was broadly flat, but margins improved substantially — approximately 450 basis points — reflecting the successful realisation of transformation benefits. The company has indicated that the full financial benefit of the Nuvisan transformation will flow through more completely in FY27.

Margin Expansion: The Operating Leverage Story

One of the most impressive aspects of ALS's FY26 results is the consistency and breadth of margin expansion across the group. The overall underlying EBIT margin of 18.0% — up 129 basis points — reflects both the natural operating leverage inherent in a testing business as volumes grow and the proactive pricing improvements that management pursued through the second half.

In Minerals specifically, the company benefitted from legacy pricing discounts rolling off as contracts came up for renewal, and management's willingness to pursue pricing in a tighter market environment. This pricing discipline, combined with operating leverage from higher sample volumes, produced the margin expansion to 33.0% that the company highlighted as a key achievement.

Capital Management and Balance Sheet Strength

ALS's balance sheet management in FY26 was notably disciplined. Free Cash Flow of $674.1 million and the benefits of the May 2025 Equity raising collectively drove the group's Leverage Ratio down from 2.3x to 1.5x EBITDA — below the lower end of the company's target range of 1.7x to 2.3x. EBITDA cash conversion was 92%, reflecting robust Working Capital Management.

Group Liquidity exceeded $580 million on a pro-forma basis as of 31 March 2026, providing a substantial war chest for the company's ongoing organic Investment program and potential bolt-on acquisitions. In May 2026, the company also successfully refinanced a maturing USD $50 million Facility for a further one-year term, reinforcing the already strong liquidity profile. The proforma weighted average Debt Maturity now stands at 4.0 years.

Capital Expenditure totalled $263 million, of which approximately $230 million was growth-related, including $93.7 million invested during FY26 as part of the four major hub laboratory expansion projects across Lima, Sydney, Bangkok, and Prague. These hub projects remain on track and on budget, with the Lima and Sydney facilities expected to be commissioned in FY27.

FY27 Outlook: Confidence Amid Macro Caution

ALS has provided an encouraging but appropriately measured outlook for FY27. At the Group level, the company is targeting mid to high single-digit organic revenue growth and margin expansion at a similar rate to FY26. For Minerals specifically, the company is guiding to 13–15% organic revenue growth for the full year, with higher confidence in 15–17% growth in H1 FY27, consistent with the strong H2 FY26 trajectory.

The company has flagged some geopolitical uncertainty, including supply chain factors specific to the Middle East conflict, estimating an Earnings risk in the order of A$5–10 million. FX headwinds are also anticipated for FY27, with every 1% movement in average FX rates for major currencies estimated to impact Underlying EBIT by approximately $3 million. Despite these considerations, ALS's procurement strategy and geographic Diversification position the group reasonably well to manage these external factors.

The Lab of the Future initiative — ALS's investment in laboratory automation, digital infrastructure, and artificial intelligence capabilities — is expected to transition from investment phase to early delivery in FY27, with more material impact expected in subsequent years.

Conclusion

ALS Limited's FY26 results represent the clearest demonstration yet of the operating leverage embedded in the company's global testing business when the commodities cycle aligns with disciplined management execution. Record revenue, record underlying NPAT, and fifth consecutive year of 30%-plus Minerals margins collectively paint the picture of a business that has capitalised on a favourable macro environment while continuing to build structural competitive advantages through hub lab investments and digital transformation. With a strong balance sheet, growing dividend, and a confident if measured FY27 outlook, ALS enters its next fiscal year from a position of considerable strategic and financial strength.